STOCK MARKET BSE NSE

Lancet study shows varying antibody levels in COVID patients

In some patients, it fluctuated and in others, the antibodies were present up to 6 months. The persistence of neutralising antibodies was associated with disease severity

Published: 26th March 2021 10:54 PM  |   Last Updated: 26th March 2021 10:54 PM   |  A+A-

A BMC volunteer wearing coronavirus themed costume participates in a COVID-19 awareness campaign in Mumbai. (Photo | PTI)

Image used for representational purposes (Photo | PTI)

Express News Service

A study published in the Lancet which studied neutralising antibody responses and duration of immunity in people who were infected with COVID-19 found that different people had varying levels of antibodies. 

Titled 'Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study' published on March 23, the study monitored neutralising antibodies in patients who had recovered from COVID-19 up to 6 months Explaining the study, Dr Ravindra Mehta, senior consultant and HOD, Pulmonology and Interventional Pulmonology, Apollo Speciality Hospitals said that while in some, the antibody levels dropped fast, in other cases it persisted. 

In some patients, it fluctuated and in others, the antibodies were present up to 6 months. The persistence of neutralising antibodies was associated with disease severity and sustained level of pro-inflammatory cytokines, chemokines, and growth factor, an excerpt of the study stated, 

"This means those who had a severe infection, with inflammation caused by cytokine storm, were found to have antibodies up to 6 months. In those, where the infection was milder and they were asymptomatic, the antibody levels were low. However, T cell immunity, which is longer memory cells, were present in people, despite neutralising antibodies going away," Dr Mehta explained. 

The rate of antibody levels waning suggests reinfection during the second and later waves of infection is likely to occur, limiting the viability of a herd immunity strategy before an effective vaccine, the study stated. Herd immunity depends on the availability of antibodies in a community but any antibodies reduce over a period of time. 

If the infection is rapid, often the T-cells are not able to remember the antibody response as the B-cells, which are the neutralising antibodies, take over to fight the present infection, said Dr Sheela Chakravarthy, Director, internal medicine, Fortis Hospitals. 

"As we do not know the response of memory T-cells, it is better to get vaccinated against COVID to stimulate them. They will thereby produce neutralising antibodies and booster doses can be given to prevent reinfection," Dr Sheela added. 

The study also revealed that patients with persistent antibodies were older and had more comorbidities, including hypertension and diabetes mellitus. 



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp